肺静脉隔离作为心力衰竭治疗的第五列:一个病例报告
Viktoria Santner1, Martin Manninger1, Anna-Sophie Eberl1
1Division of Cardiology, University Heart Center and Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, Graz 8036, Austria.
European heart journal. Case reports
|December 10, 2025
概括
Tachycardia 诱导的心肌病 (TIC) 和心力衰竭 (HF) 需要综合管理. 肺静脉隔离 (PVI) 可以改善TIC和心房的患者的左心室喷射率.
科学领域:
- 心脏病学 心脏病学
- 电力生理学 电力生理学
背景情况:
- 心力衰竭 (HF) 和心房动经常同时存在,使治疗复杂化.
- 动脉冲动引起的心肌病 (TIC) 可以发展为心脏性休克.
- 对于HF来说,指南导向的医学治疗 (GDMT) 是必不可少的.
研究的目的:
- 为了呈现一个TIC病例的进展到心脏性休克.
- 为了说明同时存在的HF和心房的管理.
- 突出肺静脉隔离 (PVI) 在TIC中的作用.
主要方法:
- 一个57岁男性的病例报告,患有新发性心房动和TIC.
- 管理包括GDMT用于HF和机械循环支持.
- 诊断工作排除了HF的其他原因.
- 在稳定后,通过PVI进行节律控制.
主要成果:
- 由于TIC,患者经历了心脏性休克.
- 最初的节律控制是不成功的,需要机械支持.
- 进行了成功的PVI.
- 在12个月的随访中,没有观察到心房的复发和改善的射出分数.
结论:
- 通过GDMT和节律/节率控制进行高频综合管理至关重要.
- 早期节律控制,包括PVI,可以成为TIC的关键治疗策略.
- 在TIC患者中,PVI可能会导致左心室喷射率的显著改善.
更多相关视频
相关概念视频
Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
554
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
554
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
277
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
277
Pulmonary Embolism III: Nursing Management
320
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
320
Heart Failure V: Medical Management
198
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
198
Cardiomyopathy II: Dilated Cardiomyopathy
436
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
436


